Showing results (1-10 of 409) with videos related to
Sort By:
Pageof 41
Muscle & Nerve|October 8, 2014
Ensuring continued progress in biomarkers for amyotrophic lateral sclerosisMartin R Turner, Michael BenatarBrain : a Journal of Neurology|October 31, 2022
Neurofilament light chain in drug development for amyotrophic lateral sclerosis: a critical appraisalMichael Benatar, Joanne Wuu, Martin R TurnerAmyotrophic Lateral Sclerosis & Frontotemporal Degeneration|March 21, 2019
Defining pre-symptomatic amyotrophic lateral sclerosisMichael Benatar, Martin R Turner, Joanne WuuCurrent Opinion in Neurology|June 29, 2023
Presymptomatic amyotrophic lateral sclerosis: from characterization to preventionMichael Benatar, Martin R Turner, Joanne WuuAmyotrophic Lateral Sclerosis & Frontotemporal Degeneration|September 25, 2015
Mind the gap: the mismatch between clinical and imaging metrics in ALSEsther Verstraete, Martin R Turner, Julian Grosskreutz, et al.Brain : a Journal of Neurology|December 10, 2024
Rethinking phase 2 trials in amyotrophic lateral sclerosisMichael Benatar, Christopher McDermott, Martin R Turner, et al.Brain and Behavior|November 6, 2024
The Basis of Cognitive and Behavioral Dysfunction in Amyotrophic Lateral SclerosisAlexander Bampton, Caroline McHutchison, Kevin Talbot, et al.Annals of Clinical and Translational Neurology|July 16, 2020
CSF chitinases before and after symptom onset in amyotrophic lateral sclerosisElizabeth Gray, Alexander G Thompson, Joanne Wuu, et al.Journal of Neurology, Neurosurgery, and Psychiatry|January 7, 2016
Increased functional connectivity common to symptomatic amyotrophic lateral sclerosis and those at genetic riskRicarda A L Menke, Malcolm Proudfoot, Joanne Wuu, et al.Neurobiology of Disease|February 16, 2007
Lost in translation: treatment trials in the SOD1 mouse and in human ALSMichael BenatarPageof 41